The study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients.
Clinical & Regulatory Affairs vice president Mark Robbins said that the Phase I/II clinical trial will provide the opportunity to demonstrate the safety and potential biological activity of DM-199 in healthy volunteers and Type 2 diabetic patients during acute and longer-term use.
"With the promising pre-clinical insulin sensitization and secretagogue activity of DM-199, we are keen to assess the anti-diabetic activity in man," Robbins added.
DiaMedica chairman and CEO Rick Pauls said that the company looks forward to having the Phase I and single dose Phase II results from the Phase I/II clinical trial in the second half of 2013.